Fennec Pharmaceuticals Inc. (TSE:FRX – Free Report) – Equities research analysts at HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a note issued to investors on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.19) per share for the quarter, up from their previous estimate of ($0.28). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.40) EPS and FY2026 earnings at $0.91 EPS.
Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.
Fennec Pharmaceuticals Trading Down 1.5 %
Shares of TSE FRX opened at C$9.12 on Thursday. The business has a fifty day simple moving average of C$9.20 and a 200-day simple moving average of C$7.92. The company has a market cap of C$175.88 million, a price-to-earnings ratio of -154.49 and a beta of 0.25. Fennec Pharmaceuticals has a 12 month low of C$5.65 and a 12 month high of C$15.20. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83.
Insider Activity at Fennec Pharmaceuticals
In related news, Director Rostislav Christov Raykov sold 10,000 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of C$8.76, for a total transaction of C$87,552.00. In the last 90 days, insiders sold 21,186 shares of company stock worth $196,017. 16.20% of the stock is owned by corporate insiders.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
See Also
- Five stocks we like better than Fennec Pharmaceuticals
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Expert Stock Trading Psychology Tips
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Breakout Stocks: What They Are and How to Identify Them
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
